Document is current
Any future updates will be listed below
-
Authors
Aguayo-Orozco, Alejandro https://orcid.org/0000-0003-1828-223X
Haue, Amalie Dahl https://orcid.org/0000-0001-7656-7976
Jørgensen, Isabella Friis https://orcid.org/0000-0001-5694-4332
Westergaard, David https://orcid.org/0000-0003-0128-8432
Moseley, Pope Lloyd
Mortensen, Laust Hvas https://orcid.org/0000-0002-6399-495X
Brunak, Søren https://orcid.org/0000-0003-0316-5866
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden (NNF14CC0001, NNF17OC0027594, NNF18SA0034956)
- License Information
-
More Information
Article History
Received: 18 May 2021
Accepted: 27 September 2021
First Online: 20 October 2021
Competing interests
: S.B. reports ownerships in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S, and managing board memberships in Proscion A/S and Intomics A/S outside the submitted work. A.A.O., A.D.H., I.F.J., D.W., P.M., and L.V.M. declare no competing interests.
